What is PanOptica?
PanOptica, Inc. is a private biopharmaceutical firm dedicated to advancing novel therapies within the field of ophthalmology. Co-founded by industry veterans Paul Chaney and Martin Wax, MD, the company focuses on translating promising early-stage assets, often derived from research in other disease areas, into human clinical proof of concept. PanOptica's strategic approach involves identifying and developing select candidates with the potential to address unmet needs in eye care, positioning it as a key player in the specialized biopharma landscape.
How much funding has PanOptica raised?
PanOptica has raised a total of $75M across 2 funding rounds:
Series A
$30M
Series B
$45M
Series A (2011): $30M with participation from Third Rock Ventures and SV Life Sciences
Series B (2014): $45M led by SV Life Sciences, Third Rock Ventures, and Novo Ventures
Key Investors in PanOptica
Third Rock Ventures
Third Rock Ventures is a healthcare venture capital firm that focuses on discovering, launching, and building companies in disruptive areas of science and medicine, aiming to make a significant impact on patient lives.
SV Life Sciences
SV Health Investors is an investment firm specializing in backing innovative healthcare and life science companies, providing capital and sector expertise to support growth and value creation.
Novo Ventures
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focused on investing in healthcare and life sciences.
What's next for PanOptica?
The substantial enterprise-level funding and recent strategic investment signal a pivotal growth phase for PanOptica. This capital infusion is expected to accelerate the company's research and development pipeline, potentially enabling the advancement of its ophthalmology therapies through critical clinical trials. The backing from prominent investors suggests a strong belief in PanOptica's ability to achieve significant milestones and bring innovative treatments to market, further solidifying its position in the competitive biopharmaceutical sector.
See full PanOptica company page
